Sensorion SA ALSEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 32.08
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Sensorion SA is a France-based clinical-stage biotech company dedicated to the development of therapies to restore, treat, and prevent hearing loss. The company's product is in phase 2a clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies. The Company does business in a single operating segment: conducting research and development to discover drugs to treat inner ear disorders with a view to their future marketing. The company's pipeline programs are SENS-401 SSNHL, SENS-401 CIO, GJB2-GT, GJB2-GT, SENS-401 Cochlear, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 57
- Website
- https://www.sensorion.com/en
Comparables
Valuation
|
Metric
|
ALSEN
|
ABVX
|
GNFT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 17.04 |
Price/Book Value | 2.73 | 3.27 | 2.65 |
Price/Sales | 32.08 | — | 3.74 |
Price/Cash Flow | — | — | 11.85 |
Price/Earnings
ALSEN
ABVX
GNFT
Financial Strength
|
Metric
|
ALSEN
|
ABVX
|
GNFT
|
|---|---|---|---|
Quick Ratio | 6.77 | 4.00 | 3.64 |
Current Ratio | 6.92 | 4.08 | 3.74 |
Interest Coverage | −137.96 | −9.89 | 5.34 |
Quick Ratio
ALSEN
ABVX
GNFT
Profitability
|
Metric
|
ALSEN
|
ABVX
|
GNFT
|
|---|---|---|---|
Return on Assets (Normalized) | −39.65% | −70.24% | 12.22% |
Return on Equity (Normalized) | −54.99% | −142.04% | 28.66% |
Return on Invested Capital (Normalized) | −54.41% | −89.54% | 17.01% |
Return on Assets
ALSEN
ABVX
GNFT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Qhdwyzdttl | Cdc | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gkwvvtpxm | Qjrtt | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hrmcslz | Mfhxj | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vgpzpdgy | Kmbtmq | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Jwqvlpdm | Pbdb | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Pdgqkcxg | Wvrk | $28.1 Bil | |||
| Moderna Inc
MRNA
| Wvgnccdn | Mlt | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Qdddmhc | Fpt | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wsvxknwjc | Smtmzsy | $13.4 Bil | |||
| Incyte Corp
INCY
| Dwlmwlrb | Hbkjnqk | $12.7 Bil |
United States